From: Comparison of hepatitis B vaccine efficacy in Japanese students: a retrospective study
Vaccine Administration route | Total number | Age range, median (IQR) | HBs antibody | Positive rate (%) | Sex | Total number | Age range, median (IQR) | HBs antibody | Positive rate (%) | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Median (IQR) | (+) | (−) | (+) | (–) | ||||||||
Bimmugen® subcutaneous | 514 | 19-25, 20 (19–21) | 84.9 (34.5–217) mIU/mL | 473 | 41 | 92.0* | Men | 204 | 19–25, 20 (19–21) | 183 | 21 | 89.1† |
Women | 310 | 19–22, 19 (19–19) | 290 | 20 | 93.5‡ | |||||||
Heptavax-II® subcutaneous | 373 | 19–30, 20 (19–21) | 28.7 (5–216) mIU/mL | 248 | 125 | 66.3* | Men | 180 | 19–30, 20 (19–21) | 102 | 72 | 56.7† |
Women | 193 | 19–22, 19 (19–19) | 146 | 7 | 75.3‡ | |||||||
Heptavax-II® intramuscular | 247 | 19–27, 20 (19–21) | 190, (41.6–534) mIU/mL | 220 | 27 | 89.1* | Men | 97 | 19–27, 20 (19–21) | 79 | 18 | 81.4† |
Women | 150 | 19–22, 19 (19–20) | 141 | 9 | 94.0‡ |